Popular New
- Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.607 daysVesikari, T(imo)Read
- Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials.623 daysVesikari, T(imo)Read
- Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age.733 daysVesikari, T(imo)Read
- Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.779 daysVesikari, T(imo)Read
- Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.810 daysVesikari, T(imo)Read
- Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study.822 daysVesikari, T(imo)Read
- Rotavirus vaccination for all children or subgroups only? Comment of the European Academy of Paediatrics (EAP) and the European Society for Paediatric Infectious Diseases (ESPID) recommendation group for rotavirus vaccination.861 daysVesikari, T(imo)Read
- Shedding of oral pentavalent bovine-human reassortant rotavirus vaccine indicates high uptake rate of vaccine and prominence of G-type G1.925 daysVesikari, T(imo)Read
- Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.931 daysVesikari, T(imo)Read
- Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines.970 daysVesikari, T(imo)Read
- Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.970 daysVesikari, T(imo)Read
- Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.1002 daysVesikari, T(imo)Read
- Continuing rotavirus circulation in children and adults despite high coverage rotavirus vaccination in Finland.1004 daysVesikari, T(imo)Read
- Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial.1019 daysVesikari, T(imo)Read
- TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines.1126 daysVesikari, T(imo)Read
- Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in Nicotiana benthamiana.1146 daysVesikari, T(imo)Read
- Rotavirus Vaccination Does Not Increase Type 1 Diabetes and May Decrease Celiac Disease in Children and Adolescents.1175 daysVesikari, T(imo)Read
- Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.1213 daysVesikari, T(imo)Read
- Development of T cell immunity to norovirus and rotavirus in children under five years of age.1219 daysVesikari, T(imo)Read
- Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.1233 daysVesikari, T(imo)Read
- Immunological Cross-Reactivity of an Ancestral and the Most Recent Pandemic Norovirus GII.4 Variant.1254 daysVesikari, T(imo)Read
- The role of the sapovirus infection increased in gastroenteritis after national immunisation was introduced.1297 daysVesikari, T(imo)Read
- Identification of a First Human Norovirus CD8+ T Cell Epitope Restricted to HLA-A*0201 Allele.1298 daysVesikari, T(imo)Read
- Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.1316 daysVesikari, T(imo)Read
- Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.1326 daysVesikari, T(imo)Read
- Implementing Universal Varicella Vaccination in Europe: The Path Forward.1333 daysVesikari, T(imo)Read
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.1378 daysVesikari, T(imo)Read
- Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigens.1379 daysVesikari, T(imo)Read
- Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.1416 daysVesikari, T(imo)Read
- Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4+ T lymphocytes with cytotoxic potential.1471 daysVesikari, T(imo)Read
- Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice.1532 daysVesikari, T(imo)Read
- Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.1544 daysVesikari, T(imo)Read
- Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged≥50 Years.1574 daysVesikari, T(imo)Read
- Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.1658 daysVesikari, T(imo)Read
- A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.1663 daysVesikari, T(imo)Read
- Report of the Fifth European Expert Meeting on Rotavirus Vaccination (EEROVAC) Utrecht, The Netherlands, 20-22 March 2017.1670 daysVesikari, T(imo)Read
- Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigens.1771 daysVesikari, T(imo)Read
- Passive enhanced safety surveillance for Vaxigrip and Intanza 15µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.1878 daysVesikari, T(imo)Read
- Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.1907 daysVesikari, T(imo)Read
- Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed In1926 daysVesikari, T(imo)Read
- Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.1958 daysVesikari, T(imo)Read
- Rotavirus epidemiology 5-6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly.2000 daysVesikari, T(imo)Read
- Epidemiology of two human protoparvoviruses, bufavirus and tusavirus.2027 daysVesikari, T(imo)Read
- Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.2029 daysVesikari, T(imo)Read
- A Phase III Randomized, Double-Blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at 2, 3, 4, and 12 Months.2056 daysVesikari, T(imo)Read
- Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland.2082 daysVesikari, T(imo)Read
- A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3, 5 and 11-12 Month Schedule.2084 daysVesikari, T(imo)Read
- Norovirus-Specific Memory T Cell Responses in Adult Human Donors.2084 daysVesikari, T(imo)Read
- Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles.2102 daysVesikari, T(imo)Read
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.2118 daysVesikari, T(imo)Read

- Medicine - All Feeds
- Allergology and Immunology
- Anatomy and Physiology
- Anesthesiology and Intensive Care
- Biochemistry
- Bioengineering
- Biophysics
- Biotechnology
- Cardiology
- Cardiothoracic Surgery
- Clinical Chemistry
- Clinical Medicine
- Complementary Medicine
- Cytology and Histology
- Dentistry
- Dermatology
- Endocrinology
- Forensic Medicine
- Gastroenterology
- General Practice
- Genetics
- Geriatrics
- Health services and Administration
- Hematology
- Infectious Diseases
- Internal Medicine
- Logopedics
- Medical Education and Humanities
- Medical Microbiology
- Medicine - Other
- Nephrology
- Neurology
- Neurosurgery
- Nursing
- Nutritional Sciences
- Obstetrics and Gynecology
- Occupational Health
- Oncology
- Ophthalmology
- Oral and Maxillofacial Surgery
- Orthopedics and Traumatology
- Otorhinolaryngology and Phoniatrics
- Pathology
- Pediatrics
- Pharmacology and Pharmacotherapy
- Physical and Rehabilitation Medicine
- Plastic Surgery
- Psychiatry
- Psychology
- Public Health
- Radiology
- Respiratory Medicine
- Rheumatology
- Sports Medicine
- Surgery
- Urology